Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do witnesses of functional/dissociative seizures recall them accurately? A UK experimental study of semiology recall at clinically relevant time points with a pilot intervention.

Epilepsia·2026
Same author

Evaluation of metformin for epilepsy prevention or seizure control in people without evidence of diabetes: retrospective cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial.

Neuro-oncology practice·2026
Same author

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
Same author

Development and Validation of Pharmacology Concept Inventory for Concept-Based Learning: Leveraging Theory, Expert Insights, and Student Perspectives.

Pharmacology research & perspectives·2026
Same author

Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.

Health technology assessment (Winchester, England)·2026

Related Experiment Video

Updated: May 2, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

13.7K

Sulthiame monotherapy for epilepsy.

Philip Milburn-McNulty1, Graham Powell, Graeme J Sills

  • 1The Walton Centre for Neurology & Neurosurgery NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool, UK, L9 7LJ.

The Cochrane Database of Systematic Reviews
|March 11, 2014
PubMed
Summary

Sulthiame (STM) monotherapy shows limited evidence for epilepsy treatment efficacy and safety. Due to small sample sizes and poor study quality, no definitive conclusions can be drawn about its use in epilepsy management.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

Related Experiment Videos

Last Updated: May 2, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

13.7K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Epilepsy is a common neurological disorder characterized by recurrent seizures.
  • Sulthiame (STM) is an antiepileptic drug frequently used in Europe and Israel.
  • This review summarizes evidence on STM's efficacy and safety as monotherapy for epilepsy.

Purpose of the Study:

  • To evaluate the efficacy of sulthiame (STM) as monotherapy in epilepsy.
  • To assess the side effect profile of STM when used as monotherapy.
  • To compare STM's effectiveness and safety against placebo or other antiepileptic drugs.

Main Methods:

  • Systematic review of randomized controlled monotherapy trials of STM.
  • Searched multiple databases including Cochrane, MEDLINE, SCOPUS, and clinical trial registries.
  • Assessed outcomes such as time to treatment failure, remission, seizure freedom, adverse effects, and quality of life.

Main Results:

  • Included studies focused on benign epilepsy of childhood with centrotemporal spikes (BECTS) and generalized tonic-clonic seizures (GTCS).
  • STM showed a significantly lower risk of gingival hyperplasia compared to phenytoin in GTCS patients.
  • Reporting of adverse events was incomplete, and data for key efficacy outcomes were largely unavailable.

Conclusions:

  • The efficacy and safety of sulthiame (STM) as monotherapy for epilepsy cannot be reliably determined.
  • Small sample sizes and poor methodological quality limit the interpretation of current evidence.
  • Further high-quality research is needed to establish the role of STM in epilepsy treatment.